Literature DB >> 8194664

Molecular model of human beta-cell glucokinase built by analogy to the crystal structure of yeast hexokinase B.

R St Charles1, R W Harrison, G I Bell, S J Pilkis, I T Weber.   

Abstract

Recent studies have shown that mutations in human beta-cell glucokinase that impair the activity of this key regulatory enzyme of glycolysis can cause early-onset non-insulin-dependent diabetes mellitus (NIDDM). The amino acid sequence of human glucokinase has 31% identity with yeast hexokinase, a related enzyme for which the crystal structure has been determined. This homology has allowed us to model the three-dimensional structure of human glucokinase by analogy to the crystal structure of yeast hexokinase B. This model of human glucokinase provides a basis for understanding the effects of mutations on its enzymatic activity. Residues in the active site and on the surface of the binding cleft for glucose are highly conserved in both enzymes. Regions far from the active site are predicted to differ in conformation, and 10 insertions or deletions that range in size from 1 to 7 residues are located on the protein surface between elements of secondary structure. The model structure suggests that human glucokinase binds glucose in a similar manner to yeast hexokinase. The glucose-binding site contains a conserved aspartic acid, two conserved glutamic acids, and two conserved asparagines that form hydrogen bond interactions with the hydroxyls of the glucose similar to those observed in other sugar-binding proteins. Mutation of residues in the predicted glucose-binding site has been found to greatly reduce enzymatic activity. This model will be useful for future structure/function studies of glucokinase.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194664     DOI: 10.2337/diab.43.6.784

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  5 in total

1.  Structure-function analysis of yeast hexokinase: structural requirements for triggering cAMP signalling and catabolite repression.

Authors:  L S Kraakman; J Winderickx; J M Thevelein; J H De Winde
Journal:  Biochem J       Date:  1999-10-01       Impact factor: 3.857

2.  ADP-dependent 6-phosphofructokinase from Pyrococcus horikoshii OT3: structure determination and biochemical characterization of PH1645.

Authors:  Mark A Currie; Felipe Merino; Tatiana Skarina; Andrew H Y Wong; Alexander Singer; Greg Brown; Alexei Savchenko; Andrés Caniuguir; Victoria Guixé; Alexander F Yakunin; Zongchao Jia
Journal:  J Biol Chem       Date:  2009-06-24       Impact factor: 5.157

3.  Effect of mutations on the sensitivity of human beta-cell glucokinase to liver regulatory protein.

Authors:  M Veiga-da-Cunha; L Z Xu; Y H Lee; D Marotta; S J Pilkis; E Van Schaftingen
Journal:  Diabetologia       Date:  1996-10       Impact factor: 10.122

4.  Kinetic studies of rat liver hexokinase D ('glucokinase') in non-co-operative conditions show an ordered mechanism with MgADP as the last product to be released.

Authors:  Octavio Monasterio; María Luz Cárdenas
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

5.  Lys169 of human glucokinase is a determinant for glucose phosphorylation: implication for the atomic mechanism of glucokinase catalysis.

Authors:  Jian Zhang; Chenjing Li; Ting Shi; Kaixian Chen; Xu Shen; Hualiang Jiang
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.